MovDisordV3, PubMed, Corpus, bibRecord, 000631

Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Identifieur interne : 000631 ( PubMed/Corpus ); précédent : 000630; suivant : 000632

Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Auteurs : Hirokazu Doi ; Ryuji Sakakibara ; Mitsutoshi Sato ; Shigekazu Hirai ; Tohru Masaka ; Masahiko Kishi ; Yohei Tsuyusaki ; Akihiko Tateno ; Fuyuki Tateno ; Osamu Takahashi ; Tsuyoshi Ogata

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.

RBID : pubmed:24375669

English descriptors

KwdEn :
- Aged, Female, Gastroparesis (drug therapy), Gastroparesis (etiology), Histamine H2 Antagonists (therapeutic use), Humans, Male, Middle Aged, Nizatidine (therapeutic use), Parkinson Disease (complications), Pilot Projects, Treatment Outcome.
MESH :
- chemical , therapeutic use : Histamine H2 Antagonists, Nizatidine.
- complications : Parkinson Disease.
- drug therapy : Gastroparesis.
- etiology : Gastroparesis.
- Aged, Female, Humans, Male, Middle Aged, Pilot Projects, Treatment Outcome.

Abstract

The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.

DOI: 10.1002/mds.25777
PubMed: 24375669

Links to Exploration step

pubmed:24375669

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.</title>
<author><name sortKey="Doi, Hirokazu" sort="Doi, Hirokazu" uniqKey="Doi H" first="Hirokazu" last="Doi">Hirokazu Doi</name>
<affiliation><nlm:affiliation>Pharmaceutical Unit, Sakura Medical Center, Toho University, Sakura, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
</author>
<author><name sortKey="Sato, Mitsutoshi" sort="Sato, Mitsutoshi" uniqKey="Sato M" first="Mitsutoshi" last="Sato">Mitsutoshi Sato</name>
</author>
<author><name sortKey="Hirai, Shigekazu" sort="Hirai, Shigekazu" uniqKey="Hirai S" first="Shigekazu" last="Hirai">Shigekazu Hirai</name>
</author>
<author><name sortKey="Masaka, Tohru" sort="Masaka, Tohru" uniqKey="Masaka T" first="Tohru" last="Masaka">Tohru Masaka</name>
</author>
<author><name sortKey="Kishi, Masahiko" sort="Kishi, Masahiko" uniqKey="Kishi M" first="Masahiko" last="Kishi">Masahiko Kishi</name>
</author>
<author><name sortKey="Tsuyusaki, Yohei" sort="Tsuyusaki, Yohei" uniqKey="Tsuyusaki Y" first="Yohei" last="Tsuyusaki">Yohei Tsuyusaki</name>
</author>
<author><name sortKey="Tateno, Akihiko" sort="Tateno, Akihiko" uniqKey="Tateno A" first="Akihiko" last="Tateno">Akihiko Tateno</name>
</author>
<author><name sortKey="Tateno, Fuyuki" sort="Tateno, Fuyuki" uniqKey="Tateno F" first="Fuyuki" last="Tateno">Fuyuki Tateno</name>
</author>
<author><name sortKey="Takahashi, Osamu" sort="Takahashi, Osamu" uniqKey="Takahashi O" first="Osamu" last="Takahashi">Osamu Takahashi</name>
</author>
<author><name sortKey="Ogata, Tsuyoshi" sort="Ogata, Tsuyoshi" uniqKey="Ogata T" first="Tsuyoshi" last="Ogata">Tsuyoshi Ogata</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24375669</idno>
<idno type="pmid">24375669</idno>
<idno type="doi">10.1002/mds.25777</idno>
<idno type="wicri:Area/PubMed/Corpus">000631</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.</title>
<author><name sortKey="Doi, Hirokazu" sort="Doi, Hirokazu" uniqKey="Doi H" first="Hirokazu" last="Doi">Hirokazu Doi</name>
<affiliation><nlm:affiliation>Pharmaceutical Unit, Sakura Medical Center, Toho University, Sakura, Japan.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name>
</author>
<author><name sortKey="Sato, Mitsutoshi" sort="Sato, Mitsutoshi" uniqKey="Sato M" first="Mitsutoshi" last="Sato">Mitsutoshi Sato</name>
</author>
<author><name sortKey="Hirai, Shigekazu" sort="Hirai, Shigekazu" uniqKey="Hirai S" first="Shigekazu" last="Hirai">Shigekazu Hirai</name>
</author>
<author><name sortKey="Masaka, Tohru" sort="Masaka, Tohru" uniqKey="Masaka T" first="Tohru" last="Masaka">Tohru Masaka</name>
</author>
<author><name sortKey="Kishi, Masahiko" sort="Kishi, Masahiko" uniqKey="Kishi M" first="Masahiko" last="Kishi">Masahiko Kishi</name>
</author>
<author><name sortKey="Tsuyusaki, Yohei" sort="Tsuyusaki, Yohei" uniqKey="Tsuyusaki Y" first="Yohei" last="Tsuyusaki">Yohei Tsuyusaki</name>
</author>
<author><name sortKey="Tateno, Akihiko" sort="Tateno, Akihiko" uniqKey="Tateno A" first="Akihiko" last="Tateno">Akihiko Tateno</name>
</author>
<author><name sortKey="Tateno, Fuyuki" sort="Tateno, Fuyuki" uniqKey="Tateno F" first="Fuyuki" last="Tateno">Fuyuki Tateno</name>
</author>
<author><name sortKey="Takahashi, Osamu" sort="Takahashi, Osamu" uniqKey="Takahashi O" first="Osamu" last="Takahashi">Osamu Takahashi</name>
</author>
<author><name sortKey="Ogata, Tsuyoshi" sort="Ogata, Tsuyoshi" uniqKey="Ogata T" first="Tsuyoshi" last="Ogata">Tsuyoshi Ogata</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Gastroparesis (drug therapy)</term>
<term>Gastroparesis (etiology)</term>
<term>Histamine H2 Antagonists (therapeutic use)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nizatidine (therapeutic use)</term>
<term>Parkinson Disease (complications)</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Histamine H2 Antagonists</term>
<term>Nizatidine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gastroparesis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gastroparesis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24375669</PMID>
<DateCreated><Year>2014</Year>
<Month>04</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>12</Month>
<Day>03</Day>
</DateCompleted>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>4</Issue>
<PubDate><Year>2014</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.</ArticleTitle>
<Pagination><MedlinePgn>562-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25777</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax ((13) C) (the peak time of the (13) C-dose-excess curve) (P < 0.05).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients.</AbstractText>
<CopyrightInformation>© 2013 International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doi</LastName>
<ForeName>Hirokazu</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Pharmaceutical Unit, Sakura Medical Center, Toho University, Sakura, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sakakibara</LastName>
<ForeName>Ryuji</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sato</LastName>
<ForeName>Mitsutoshi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hirai</LastName>
<ForeName>Shigekazu</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Masaka</LastName>
<ForeName>Tohru</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kishi</LastName>
<ForeName>Masahiko</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tsuyusaki</LastName>
<ForeName>Yohei</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tateno</LastName>
<ForeName>Akihiko</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tateno</LastName>
<ForeName>Fuyuki</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Takahashi</LastName>
<ForeName>Osamu</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ogata</LastName>
<ForeName>Tsuyoshi</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>12</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006635">Histamine H2 Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>P41PML4GHR</RegistryNumber>
<NameOfSubstance UI="D016567">Nizatidine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018589">Gastroparesis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006635">Histamine H2 Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016567">Nizatidine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword>
<Keyword MajorTopicYN="N">gastric emptying</Keyword>
<Keyword MajorTopicYN="N">gastroparesis</Keyword>
<Keyword MajorTopicYN="N">levodopa</Keyword>
<Keyword MajorTopicYN="N">nizatidine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>7</Month>
<Day>4</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>11</Month>
<Day>6</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>11</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year>
<Month>12</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24375669</ArticleId>
<ArticleId IdType="doi">10.1002/mds.25777</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000631 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000631 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24375669
   |texte=   Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24375669" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki